Resolian Executive and Leadership Team

Robert Stachlewitz, the Chief Executive Officer at Resolian, directs the overarching corporate strategy and operational framework. Stachlewitz guides the integration of Alliance Pharma and Drug Development Solutions' expertise, ensuring seamless collaboration across all therapeutic modalities. This leadership role involves setting the company's vision and driving its mission to provide world-class scientific solutions. Overseeing key strategic initiatives, the Chief Executive Officer ensures alignment with market demands and fosters an environment of continuous innovation. By championing cross-functional partnerships, Robert Stachlewitz enhances Resolian's capacity to deliver impactful advancements in drug development and therapeutic research. The Chief Executive Officer's focus remains on expanding the company's global reach and solidifying its position as a leader in the R&D services sector.

Alexander Abramov, the Chief Financial Officer at Resolian, manages all financial operations and fiscal strategy. Abramov oversees budgeting, forecasting, and financial reporting, ensuring robust fiscal health for the organization. This critical position involves optimizing financial resources to support Resolian's collaborative efforts in therapeutic modalities. The Chief Financial Officer drives financial planning to facilitate the fusion of expertise from Alliance Pharma and Drug Development Solutions. By implementing stringent financial controls and identifying strategic investment opportunities, Alexander Abramov strengthens Resolian's ability to deliver world-class scientific solutions. Abramov's leadership ensures financial stability and supports the company's growth objectives in the competitive R&D landscape.

Laixin Wang, the President, Site (China) at Resolian, leads all operational activities and strategic development within the China region. Wang directs the execution of Resolian's scientific solutions, ensuring adherence to global standards while adapting to local market dynamics. This executive role is pivotal in fostering collaborations and integrating expertise from Alliance Pharma and Drug Development Solutions within the Chinese market. The President, Site (China) oversees the site's contribution to therapeutic modality advancements. By managing regional resources and driving operational efficiency, Laixin Wang enhances Resolian's presence and impact in China. Wang's leadership ensures the site's success in delivering world-class R&D services and supporting the company's broader mission.

Jason Wang, the President, Site (Australia) at Resolian, spearheads the operational management and strategic direction for the Australian site. Wang ensures the effective implementation of Resolian's world-class scientific solutions across therapeutic modalities in the Australian market. This leadership position is key to integrating the combined expertise of Alliance Pharma and Drug Development Solutions within the region. The President, Site (Australia) oversees the site's performance and its contribution to the company's overall objectives. By optimizing local operations and fostering strategic partnerships, Jason Wang drives growth and innovation. Wang's focus remains on enhancing Resolian's capabilities and solidifying its reputation for excellence in Australia.